Objectives: We identified Staphylococcus aureus strains having blunt inhibitory zones around the clindamycin or josamycin discs proximal to the erythromycin disc filled with slight bacterial growth. This ambiguous phenotype was termed as 'macrolide-lincosamide-streptogramin B antimicrobial (MLS B ) resistance having a foggy D-shaped inhibitory zone' (fMLS B ), and we tried to analyse its molecular mechanisms.
Introduction
Staphylococcal resistance to the macrolide -lincosamidestreptogramin B antimicrobials (MLS B ) is mostly mediated by erythromycin ribosome methylase (erm) genes. 1, 2 In particular, the erm(A) gene is the most predominant molecular mechanism among clinically isolated MLS B -resistant Staphylococcus aureus forms. 3 The erm(A) gene encodes ribosomal methylase and the expression is regulated by translational attenuation. Ribosomal RNA methylation leads MLS B antibiotics not to bind to the ribosome, cross-resistance and peculiar phenotypes, including inducible (iMLS B ) and constitutive MLS B resistance (cMLS B ). 1 The phenotype of the wild-type erm(A) gene is iMLS B owing to an alteration of the mRNA secondary structure by induction and ribosomal stalling by erythromycin. 4 Certain mutations in the regulatory region make the stem and loop of the mRNA structure unstable and allow translation of erm(A) transcripts independent of the presence or absence of inducers, 3, 5 which results in the phenotype cMLS B . In the case of staphylococcal MLS B resistance, these phenotypes predict the susceptibility to lincosamides, 16-membered macrolides and ketolides. 3, 5, 6 Thus, the report of an accurate phenotype for MLS B resistance is important to determine the proper therapeutic strategy. 7 -9 In a previous study, we identified an ambiguous phenotype among clinically isolated S. aureus. 10 There were blunt inhibitory zones around the clindamycin or josamycin discs proximal to the erythromycin disc filled with slight bacterial growth. We termed this phenomenon 'MLS B resistance having a foggy D-shaped inhibitory zone' (fMLS B ). This phenotype was introduced previously in a case report. 7, 8 Furthermore, we have reported that the fMLS B phenotype was detected in 9% on average among the MLS B -resistant S. aureus strains in Korea; 10.8% in 1999, 8% in 2001, 4.8% in 2003, and 9% in 2005, and all the fMLS B S. aureus strains had only the erm(A) gene. 10 The aim of this study was to define the fMLS B phenotype and analyse its molecular mechanisms.
Materials and methods

Bacterial strains
Forty-one clinically isolated S. aureus strains exhibiting foggy D-shaped blunt zone of inhibition around the disc containing clindamycin (2 mg) proximal to the erythromycin (20 mg) disc were studied. 
Determination of the phenotype of D-shaped zone of inhibition
All 41 strains were tested by a disc diffusion method. An aqueous suspension of bacterial growth was adjusted to an optical density of 0.5 at 600 nm (OD 600 ) and inoculated by swab on Mueller -Hinton (MH) agar (Difco, USA; 20 mL in a plate with a diameter of 89 mm). Each plate was set with six discs as shown in the righthand panels of Figure 1 . This arrangement allowed observation of both the growth inhibition under various concentrations (0.1, 1, 10, 100 and 1000 mg) of clindamycin and its resistance inducibility by erythromycin (20 mg). For another observation, an aqueous bacterial suspension was adjusted to an OD 600 of 0.5, and then 0.1 mL of 10 5 -fold diluted bacterial suspension was inoculated on MH agar. Each plate was set with erythromycin (20 mg) and clindamycin (100 mg) discs, as shown in the left-hand panels of Figure 1 . This arrangement was made in order to compare the size of the bacterial colonies inside and outside of the D-zone. All the aspects were identified after overnight incubation at 378C.
Induction assay
To test inducibility, the growth rate of the strains under clindamycin was determined after induction by erythromycin. Bacterial cultures grown overnight in MH broth without antibiotic were diluted to an OD 600 of approximately 0.05 in MH broth. After induction by incubation with 0.2 mg/L erythromycin for 2 h, the cultures were diluted again to an OD 600 of approximately 0.05 in MH broth. Growth under 100 mg/L clindamycin at 378C was monitored by measuring the turbidity of the culture at OD 600 for up to 8 h. Cultures under no challenge or induction were also observed for comparison. Strains resistant to MLS B , i.e. iMLS B and cMLS B strains, were observed under the same conditions for comparison.
Analysis of the regulatory regions of the erm(A) gene
The sequences of the erm(A) regulatory regions of 41 strains were analysed. DNA fragments were amplified by PCR using the primers, ERMA-F (5 0 -gaagtcgtcaaggtgcaaaattac-3 0 ) and ERMA-R (5 0 -gactagctctttggtaaaatgtcc-3 0 ), designed to amplify DNA fragments of the regulatory region including the promoter and the first 147 bases of the erm(A) gene. PCR experiments were carried out as follows: 25 cycles of amplification including 10 s of denaturation at 978C, 30 s of annealing at 478C and 40 s of elongation at 748C. The PCR products were purified with a PCR purification kit (INtRON, Korea) and sequenced by using the primer ERMA-F with an ABI 3730XL DNA Analyzer (Applied Biosystems, USA). According to the sequencing electropherograms, we divided the fMLS B strains into two groups: a homogeneous nucleotide sequence group and a heterogeneous nucleotide sequence group (Figure 3 ). These two groups were then analysed further in different aspects.
Construction of erm(A)-lacZ reporter plasmids and b-galactosidase assay
Through sequencing, the homogeneous nucleotide sequence group was proven to be composed of two mutation types: a 25 bp tandem duplication and a 25 bp tandem triplication. To analyse them, in-phase fusions of the erm(A) regulatory region with lacZ were constructed; pIND having the wild-type erm(A) regulatory region of Tn554, pTD having the 25 bp tandem duplicate erm(A) regulatory region and pTT having the 25 bp tandem triplicate erm(A) regulatory region. The regulatory region of the erm(A) gene was amplified with the primers ERMA-ECORIF (5 0 -atctgaattcgtcaaggtgca-3 0 ) for the 5 0 end and ERMA-BAMHIR (5 0 -acataagcctggatccatttc-3 0 ) for the 3 0 end. The PCR products were purified and ligated to the EcoRI and BamHI sites of pMM156 containing a promoterless lacZ gene. 11 The resultant ligation products were introduced into Escherichia coli NM522, and transformants were selected on Luria-Bertani agar plates containing chloramphenicol (10 mg/L). Bacillus subtilis BR151 strains harbouring each confirmed recombinant plasmid were grown to early log phase at 378C in SPII medium, and b-galactosidase assays were carried out as described previously. 12 Cultures were induced for 50 min with either erythromycin or clindamycin under various concentrations, and the optimal concentration for the induction was determined. The b-galactosidase assays were carried out after induction by 0.1 mg/L erythromycin, and Miller units at 0, 5, 10, 20, 30, 45 and 60 min were measured.
In the case of the heterogeneous nucleotide sequence group, we could not determine the exact nucleotide sequence directly. Thus, multiple in-phase fusions of the erm(A) regulatory region with lacZ from each isolate were constructed. The regulatory region of the erm(A) gene was amplified with the primers ERMA-ECORIF for the 5 0 end and ERMA-BAMHIR for the 3 0 end. The purified PCR products were ligated to pMM156 and the recombinant plasmid was introduced into E. coli NM522. Numerous transformants were selected and plasmids were extracted. Also, the plasmids were introduced, respectively, into B. subtilis BR151. Then, b-galactosidase assays were carried out and Miller units at 0, 15, 30, 60 and 90 min after induction by 0.1 mg/L erythromycin were measured. For further sequencing, we classified the plasmids into several groups by the expression pattern of the b-galactosidase assay, and then sequencing of more than three randomly selected plasmids for each expression pattern was conducted.
Results and discussion
Expression of fMLS B resistance
All the 41 fMLS B S. aureus strains exhibited a foggy D-shaped zone of inhibition around the disc containing clindamycin proximal to the erythromycin disc. The size of the D-shaped zone was dependent on the concentrations of clindamycin, as in the case of iMLS B (Figure 1, the right-hand column) . Also, we could observe slight growth inside the D-shaped zone. This growth was confirmed by comparing the colony size inside and outside of the D-shaped zone ( Figure 1 , the left-hand column). The colony size inside was smaller than that outside of the D-shaped zone. To observe the influence of clindamycin challenge before and after induction by erythromycin, the growth rate of the representative fMLS B strain was measured in broth under various conditions (Figure 2 ). When the fMLS B strain was not induced by erythromycin, the growth rate was inhibited slightly by clindamycin. However, its repressed growth under clindamycin recovered to the level of the cMLS B strain after induction by erythromycin. Similar results were obtained with other fMLS B strains (data not shown).
The foggy D-shaped inhibitory zone of the fMLS B strain appeared gradually on the agar plate. Initially, it seemed that only the clear D-shaped inhibitory zone had appeared. However, with the lapse of time, the clear D-shaped inhibitory zone became foggy (data not shown). With this phenomenon, we propose that the formation of the foggy D-shaped zone proceeds step by step, in the following order. First, the fMLS B strain grows in a manner similar to the iMLS B strain; its growth is inhibited by clindamycin and the resistance is induced by erythromycin, and naturally, it makes a clear D-shaped zone. After that, the growth around the clindamycin disc recovers from the repression like the cMLS B strain, and small colonies start to appear in the D-shaped zone. The observation of the phenomenon of the similar growth curve in broth of the fMLS B strain may also support this suggestion. Growth was repressed under clindamycin in the early stage of the curve, but ultimately recovered back to the level of the cMLS B strain. 
Analysis of the regulatory region of the erm(A) gene
Using the oligonucleotides ERMA-F and ERMA-R, we obtained amplicons of the erm(A) regulatory regions from all the 41 strains and they were sequenced as described previously. The sequencing electropherograms revealed that two groups of the erm(A) translational attenuator were available: a homogeneous nucleotide sequence group and a heterogeneous nucleotide sequence group. The homogeneous nucleotide sequence group showed clear single peaks, but the heterogeneous nucleotide sequence group displayed the coexistence of two peaks in such a manner that two nucleotide sequences were merged (Figure 3) .
Among all the 41 fMLS B strains investigated, 30 isolates (73.2%) belonged to the homogeneous nucleotide sequence group. The homogeneous nucleotide sequence group was composed of two mutation types: the 25 bp tandem duplication type Table 1 ). Four isolates (9.8%) were of the 25 bp tandem triplication type, in which the same site of the 25 bp duplication type was triplicated [ Figure 4 (b3) ]. These alterations, i.e. the 25 bp tandem duplication and triplication, did not result in a frame-shift. Duplication or triplication of the 25 bp nucleotides generated one successive stop codon after three valid codons, resulting in a truncated peptide of three amino acids ( Figure 5) . Thus, the erm(A) gene would start to translate again and be completely formed into the methylase.
Among the 41 fMLS B strains, 11 isolates (26.8%) displayed merged nucleotide sequences starting from a specific base pair (Figure 3) . We speculated that the coexistence of the two peaks was due to the coexistence of two different DNA sequences in a single isolate. Therefore, we tried to separate the nucleotides and analysed the constructs individually.
Analysis of a homogeneous nucleotide sequence group
In the case of the homogeneous nucleotide sequence group, we performed b-galactosidase assays with reporter constructs. The regulatory region and truncated methylase genes were translationally fused with E. coli lacZ, and three kinds of recombinant plasmids were obtained, pIND, pTD and pTT, which were constructed as described previously. b-Galactosidase activity was measured with B. subtilis BR151 carrying pIND, pTD and pTT, respectively, under various concentrations of erythromycin or clindamycin. For plasmid pIND, erythromycin was a potent inducer at concentrations of 0.01 and 0.1 mg/L. The basal level of the erm(A) expression of pIND was low, and the expression level increased 3.9-and 4.6-fold during 50 min of induction at 0.01 and 0.1 mg/L erythromycin, respectively. In contrast to pIND, the basal levels of expression of pTD and pTT were drastically high; 21.3-and 24.7-fold higher than pIND, respectively (data not shown). b-Galactosidase activity at various times after treatment with the optimal concentration of 0.1 mg/L erythromycin also showed that pTD and pTT were not induced by erythromycin ( Figure 6 ).
The 25 bp tandem duplicate and triplicate nucleotide sequences did not include part of the inverted repeats, and thus the mRNA secondary structures were maintained ( Figure 5 ). Because their mRNA secondary structures are the same as the wild-type erm(A) regulatory region, 13, 14 the same process of denaturing the secondary structure and inducible exhibition of the primary SD3 might be a possibility in vivo, even though we could not observe the phenomenon in the b-galactosidase assay in vitro.
Analysis of a heterogeneous nucleotide sequence group
The typical Tn554 containing the erm(A) gene is known to exist as one or two copies per chromosome. 15, 16 To confirm that the erm(A) gene does exist in the fMLS B S. aureus strain in the typical mode, we performed Southern blotting. 17 Visual inspection and densitometric analysis revealed that the copy numbers of the erm(A) gene were all similar and not affected by the phenotype (data not shown). Thus, the analysis of strains in the heterogeneous nucleotide sequence group was performed on the premise that there is/are one or two erm(A) copies per chromosome. We tried to verify the individual genes by multiple molecular cloning and respective characterization. The typical molecular cloning method is performed to obtain information on one specific gene on the assumption that only one type of gene exists per isolate. However, in this case, we performed the molecular cloning to characterize one or two genes of one isolate. Thus, we named this 'the multiple molecular cloning method' and carried it out. First, we selected numerous transformed E. coli NM522 for each fMLS B isolate and extracted their corresponding plasmids. We had analysed all the recombinant plasmids in B. subtilis by b-galactosidase assay and grouped all the plasmids into several types according to their expression patterns. Also, more than three plasmids in each expression pattern were sequenced. Some plasmids in the different expression patterns displayed the same sequencing results, so that ultimately only three alterations were identified (Figure 4 ). According to the results, three mixture types were determined (Table 1) : a mixture of the wild-type erm(A) attenuator and the two point mutations T5361G and G5288T, eight cases (19.5% among 41 fMLS B strains); a mixture of the 25 bp tandem duplication and the 25 bp tandem triplication, two cases (4.9%); and a mixture of the wild-type erm(A) attenuator and the 25 bp tandem duplication, one case (2.4%). The coexistence of the two expression types is represented in Figure 7 as the result of b-galactosidase assays. When the alteration of two nucleotides, T5361G and G5288T, was in the homogeneous nucleotide sequence group, the phenotype was typical cMLS B (data not shown). Accordingly, the coexistence of two genes, a wild-type erm(A) attenuator and the two point mutations, may result in the dual characteristic phenotype, fMLS B . The 25 bp tandem duplication or triplication types were introduced, respectively, in the homogeneous nucleotide sequence group showing the 
Conclusions
We observed the fMLS B isolates among the clinically isolated forms of S. aureus. Furthermore, the alteration of the erm(A) regulatory region, which was regarded as the only mechanism, was analysed. Two groups of mutation types were identified according to the sequencing electropherograms. One was the homogeneous nucleotide sequence group having the alteration of a 25 bp tandem duplication or triplication. Although their expression pattern seemed to be of a cMLS B type in a b-galactosidase assay in vitro, their predicted mRNA secondary structures suggest that they might possess both inducible and constitutive characters simultaneously in vivo. The other was the heterogeneous nucleotide sequence group, in which two different erm(A) regulatory regions were found in a single isolate. The strains in this group were considered to have dual characters, one from each gene. These two different groups display both inducible and constitutive expression. In conclusion, the phenotype fMLS B is due to possession of the inducible and constitutive resistance expression characters at once.
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Supplementary data
Colour versions of Figures 3 and 5 are available as Supplementary data at JAC Online (http://jac.oxfordjournals.org/). Figure 6 . Expression patterns of erm(A) of the strains in the homogeneous nucleotide sequence group by the b-galactosidase assay. B. subtilis BR151 strains carrying the respective plasmids, pTD, pTT and pIND, were used. pTD, the construct with the 25 bp tandem duplicate erm(A) regulatory region (type a of Table 1 ); pTT, the construct with the 25 bp tandem triplicate erm(A) regulatory region (type b of Table 1 ); pIND, the construct with the inducible wild-type erm(A) regulatory region. b-Galactosidase activity was measured after induction with 0.1 mg/L erythromycin (filled circles) or not pre-treated (open circles). Table 1 ), pIND and pTD (type c of Table 1) , and pTD and pTT (type e of Table 1 ) were used. These pairs of erm(A) genes originated from the clones of each fMLS B strain in the heterogeneous nucleotide sequence group (types c-e of Table 1 ). pPM was the construct with the erm(A) regulatory region with the two point mutations T5361G and G5288T. b-Galactosidase activity was measured after induction with 0.1 mg/L erythromycin.
